M
Michael A. Heneghan
Researcher at University of Cambridge
Publications - 289
Citations - 10869
Michael A. Heneghan is an academic researcher from University of Cambridge. The author has contributed to research in topics: Liver transplantation & Autoimmune hepatitis. The author has an hindex of 51, co-authored 245 publications receiving 9041 citations. Previous affiliations of Michael A. Heneghan include National Health Service & King's College.
Papers
More filters
Journal ArticleDOI
Aerobic capacity during cardiopulmonary exercise testing and survival with and without liver transplantation for patients with chronic liver disease
William Bernal,Rosa Martin-Mateos,Miklos Lipcsey,Caroline Tallis,Kyne Woodsford,Mark J. W. McPhail,Christopher Willars,Georg Auzinger,Elizabeth Sizer,Michael A. Heneghan,Simon Cottam,Nigel Heaton,Julia Wendon +12 more
TL;DR: In patients who did not undergo transplantation, impaired AT was predictive of mortality, and in patients undergoing LT, it was related to postoperative hospitalization and survival, and AC should be evaluated as a modifiable factor for improving patient survival whether or not LT is anticipated.
Journal ArticleDOI
Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis
Cumali Efe,Hannes Hagström,Henriette Ytting,Rahima A. Bhanji,Niklas F. Müller,Qixia Wang,Tugrul Purnak,Luigi Muratori,Mårten Werner,Hanns-Ulrich Marschall,Paolo Muratori,Fulya Gunsar,Daniel Klintman,Albert Parés,Alexandra Heurgué-Berlot,Thomas D. Schiano,Mustafa Cengiz,Michele M. Tana,Xiong Ma,Aldo J. Montano-Loza,Thomas Berg,Sumita Verma,Fin Stolze Larsen,Ersan Ozaslan,Michael A. Heneghan,Eric M. Yoshida,Staffan Wahlin +26 more
TL;DR: Long‐term therapy with MMF or tacrolimus generally was well tolerated by patients with AIH and the agents were equally effective in previous complete responders who did not tolerate SOC therapy.
Journal ArticleDOI
Hepatic Dysfunction in Sickle Cell Disease: A New System of Classification Based on Global Assessment
Philip A. Berry,Timothy J.S. Cross,Swee Lay Thein,Bernard Portmann,Julia Wendon,John Karani,Michael A. Heneghan,Adrian Bomford +7 more
TL;DR: In this paper, the clinical, laboratory, radiographic, and histologic features with the natural history of 38 patients with Hb SS, SC, or S-β thalassemia referred to a tertiary liver center for assessment were reviewed.
Journal ArticleDOI
In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression.
Rodrigo Liberal,Rodrigo Liberal,Charlotte R. Grant,Beth Holder,John Cardone,Marc Martinez-Llordella,Yun Ma,Michael A. Heneghan,Giorgina Mieli-Vergani,Diego Vergani,Maria Serena Longhi +10 more
TL;DR: In AILD, bona‐fide Tregs produce less interleukin (IL)−10 and are impaired in their ability to suppress CD4+CD25− target cell proliferation, a feature that in HSs, but not in AILDs, is dependent, at least in part, on IL‐10 secretion.
Journal ArticleDOI
The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis.
Deepak Joshi,Ingvar Bjarnason,Ajay P. Belgaumkar,John O'Grady,Abid Suddle,Michael A. Heneghan,Varuna Aluvihare,Mohammed Rela,Nigel Heaton,Kosh Agarwal +9 more
TL;DR: An association between primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) is well recognized but the disease course of IBD following liver transplantation (LT) for PSC remains ill‐defined.